H.D. Perez – författare

The therapeutic options for the treatment of multiple sclerosis (MS) and other neurodegenerative and traumatic diseases such as spinal cord injury, Alzheimer's, Parkinson's disease, etc. , have undergone enormous progress over recent years. Despite these encouraging developments, available therapies are only partially effective, and the ultimate goal is still far from being attained. Improved understanding of the cellular and molecular mechanisms of the pathogenesis of neurodegeneration and demyelination has led to a variety of new therapeutic targets and approaches. In addition to modulation of the in?ammatory process (MS) and cl- sical neuroprotection (stroke, AD), therapeutic approaches focussing on active remyelinization and neuronal regeneration have become incre- ingly important. Based on current concepts, this book summarizes new therapeutic approaches. Although it was once thought that the central nervous system (CNS) of mammals was incapable of substantial recovery from injury, it is now clear that the adult CNS remains responsive to various substances that can promote cell survival and stimulate axonal growth.Among these substances are growth factors, including the neurotrophins and cytokines. Stem cell therapies for the induction of remyelinization and neuroregeneration are reviewed. The potential role of a protective - munity in the induction of remyelination and neuroregeneration is also discussed. Different gene therapy approaches for the treatment of MS VI Preface and other neurodegenerative diseases such as Alzheimer's disease and spinal cord injury, etc. , are also summarized.

The therapeutic options for the treatment of multiple sclerosis (MS) and other neurodegenerative and traumatic diseases such as spinal cord injury, Alzheimer's, Parkinson's disease, etc. , have undergone enormous progress over recent years. Despite these encouraging developments, available therapies are only partially effective, and the ultimate goal is still far from being attained. Improved understanding of the cellular and molecular mechanisms of the pathogenesis of neurodegeneration and demyelination has led to a variety of new therapeutic targets and approaches. In addition to modulation of the in?ammatory process (MS) and cl- sical neuroprotection (stroke, AD), therapeutic approaches focussing on active remyelinization and neuronal regeneration have become incre- ingly important. Based on current concepts, this book summarizes new therapeutic approaches. Although it was once thought that the central nervous system (CNS) of mammals was incapable of substantial recovery from injury, it is now clear that the adult CNS remains responsive to various substances that can promote cell survival and stimulate axonal growth.Among these substances are growth factors, including the neurotrophins and cytokines. Stem cell therapies for the induction of remyelinization and neuroregeneration are reviewed. The potential role of a protective - munity in the induction of remyelination and neuroregeneration is also discussed. Different gene therapy approaches for the treatment of MS VI Preface and other neurodegenerative diseases such as Alzheimer's disease and spinal cord injury, etc. , are also summarized.

Over the last few years, we have witnessed tremendous progress in the field of eicosanoids and their therapeutic applications. Receptor an­ tagonists for leukotrienes have been tested as anti-inflammatories and are on the market as a treatment for asthma. Receptor agonists for pro­ stacyclin are being tested for the treatment of peripheral vascular dis­ ease, and selective inhibitors of cyclooxygenase type II were just ap­ proved for the treatment of rheumatoid arthritis. All these developments are the culmination of many years and man-hours of careful research. The field has now entered an upswing that will result in novel thera­ peutic applications within the next 10 years. New molecules and me­ diators have been identified, new enzymes and pathways elucidated and new therapeutic approaches have emerged. The concept of ei­ cosanoids as "pro-inflammatory" molecules is being challenged, and their role as regulators is increasingly recognized. In fact, some of these molecules may be important endogenous anti-inflammatory agents.